

EMLc

ATC codes: P02CA03

|                          |   |
|--------------------------|---|
| Indication               | Lymphatic filariasis <span style="border: 1px solid #ccc; padding: 2px;">ICD11 code: 1F66.3</span>  |
| INN                      | Albendazole   |
| Medicine type            | Chemical agent  |
| List type                | Core (EML)<br>(EMLc)  |
| Formulations             | Oral > Solid > tablet: 400 mg (chewable, scored)  |
| EML status history       | First added in 2011 (TRS 965)<br>Changed in 2023 (TRS 1049)   |
| Sex                      | All   |
| Age                      | Also recommended for children   |
| Therapeutic alternatives | The recommendation is for this specific medicine  |
| Patent information       | Patents have expired in most jurisdictions<br>Read more <a href="#">about patents</a> .  |
| Wikipedia                | <a href="#">Albendazole</a>   |
| DrugBank                 | <a href="#">Albendazole</a>    |

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listings for albendazole 400 mg chewable tablets on the EML and EMLc be amended to specify that they be scored.

